Vertex Pharmaceuticals (VRTX) has entered into a three-year research collaboration with Orna Therapeutics to develop gene editing therapies for sickle cell disease and transfusion-dependent beta thalassemia, Orna said Tuesday.
The collaboration will use Orna's lipid nanoparticle delivery system to advance Vertex's therapeutic development, Orna said.
Under the agreement, Orna said it will receive $65 million upfront, including a convertible note investment, and could earn up to $635 million based on achieving milestones for SCD/TDT products.
Orna said it is eligible for up to $365 million in additional option fees and milestones per product for up to 10 additional products if Vertex exercises rights for new indications, and will also receive tiered royalties on future sales. Vertex is financing the research collaboration and has the option to extend its duration.
Shares of Vertex were up 1.9% in recent Tuesday trading.
Price: 409.97, Change: +7.48, Percent Change: +1.86
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。